Who we are

BioCurate is a bold, collaborative venture, dedicated to translating Australian medical research and delivering health and economic benefits to the world. Created jointly by two of Australia’s leading biomedical universities, the University of Melbourne and Monash University, we are operationally independent with an absolute commitment to rigorous science and partnering closely with researchers to help conquer the challenges which stand between great ideas and global impact. We can help you change the future.

We bridge the gap

Our collaborative team of global biomedical experts bridge the gap between:

Academia + Industry
Ideas + Impact
Discovery + Partnerships
Collaboration + Commercialisation
Research + Translation

What we are doing

Staff profiles

Our team

150
Has over 150 years of combined biotech/pharma industry experience

35
Has been directly involved in over 35 Investigational New Drug applications (INDs)

70
Are responsible for 70 therapeutics currently in the clinic

$2.1B
Were directly involved in 15 deals worth a cumulative total of over $2.1 billion

Twitter feed

Calling all @MonashUni researchers based at @AlfredHealth! BioCurate's Damien Bates & Andy Allen will be hosting an online information session on 29 July about BioCurate, BioCurate’s project evaluation, selection, and funding process. More details below.

What is needed to establish “proof of concept (POC)” in preclinical studies? At the early stage of a drug development program, human genetic evidence linking a proposed target to a disease provides powerful evidence supporting POC. Read more: https://www.biocurate.com/resources/proof-of-concept-industrys-perspective/

What is 'proof of concept (POC)?' For industry, POC almost always applies to clinical trials. However, to the academic researcher, POC is often defined differently. How do we ensure clarity and specificity? Find out: https://bit.ly/3wOUQuO